Fuente: FierceBiotech uniQure’s Huntington’s disease gene therapy has failed to significantly slow disease progression after 48 months, sending the biotech’s stock down 41% when trading began. But mitigating circumstances and the ongoing strength of a secondary endpoint kept analysts optimistic about AMT-130’s path to approval.